Biotek-snakken — December 2021
-
Lexus….man kan vel sige at HVIS deres planer lykkedes, kan det være en god langsigtet aktie, med meget mindre risiko og udgifter til godkendelses proceduren. Prøv at se nogle af deres præsentationer her fra hjemmesiden: https://xbrane.com/en/investors-media/presentations-2/
-
Immunic's IMU-935 Demonstrates
Favorable Safety Profile In Phase I Trial https://www.proinvestor.com/investornyt/749109/immunics-imu-935-demonstrates-favorable-safety-profile-in-phase-i-trial -
Shares of Galera Therapeutics Inc. (GRTX) skyrocketed 95% on Tuesday, thanks to corrected results from its ROMAN trial...https://www.proinvestor.com/investornyt/749535/a-second-look-at-galera-therapeutics
-
Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis https://www.proinvestor.com/investornyt/749759/nektar-announces-positive-phase-1b-data-for-nktr-358-in-patients-with-atopic-dermatitis
-
Novavax: Partner Takeda Submits NDA In Japan For Approval Of COVID-19 Vaccine https://www.proinvestor.com/investornyt/750161/novavax-partner-takeda-submits-nda-in-japan-for-approval-of-covid-19-vaccine
-
FDA Grants Calliditas Accelerated Approval Of Tarpeyo To Reduce Proteinuria In IgA Nephropathy https://www.proinvestor.com/investornyt/750155/fda-grants-calliditas-accelerated-approval-of-tarpeyo-to-reduce-proteinuria-in-iga-nephropathy
-
Innate : First Patient Dosed In
IPH6101/SAR443579 Phase 1/2 Trial In Various Blood Cancers https://www.proinvestor.com/investornyt/750170/innate-first-patient-dosed-in-iph6101-sar443579-phase-1-2-trial-in-various-blood-cancers -
Better safe than worry. Sådan indleder
Helge Larsen investorernes reaktion på centralbankernes udmeldinger. Han samler desuden op på debatten om Zealand Pharma og Genmab og kommer ind på de nye chats, der er oprettet på ProInvestor.com https://www.proinvestor.com/index.php?p=debat_1&postid=99494 -
Servicemeddelelse: Nye chatgrupper: Pharma, Krypto, Amerikanske aktier.
-
Godt nyt fra ViroGates. Kan godt komme til at betyude meget for selskabet. https://view.news.eu.nasdaq.com/view?id=b487a1b3c69c03814f4b13ec235724639&lang=en
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind